scholarly journals Low-Dose Fulvestrant Maintained Long-Term Complete Remission after Poor Response to Previous Endocrine Therapies in a Patient with Advanced Breast Cancer

2010 ◽  
Vol 3 (2) ◽  
pp. 131-136
Author(s):  
H. Hawle ◽  
D. Hess ◽  
A. Mueller ◽  
B. Thuerlimann
Keyword(s):  
Breast Cancer ◽  
Complete Remission ◽  
Advanced Breast Cancer ◽  
Low Dose ◽  
Poor Response ◽  
Advanced Breast

scholarly journals Second-line chemotherapy with long-term low-dose oral etoposide in patients with advanced breast cancer

1995 ◽  
Vol 34 (2) ◽  
pp. 185-189 ◽  
Author(s):  
M. Bontenbal ◽  
A. S. Th. Planting ◽  
J. Verweij ◽  
R. de Wit ◽  
W. H. J. Kruit ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Low Dose ◽  
Advanced Breast ◽  
Oral Etoposide ◽  
Second Line ◽  
Second Line Chemotherapy ◽  
Dose Oral ◽  
Line Chemotherapy

Cisplatin and VP16 in Metastatic Breast Carcinoma as a Third-Line Chemotherapy: A Randomized Study Comparing Low versus High Doses of Cisplatin

1995 ◽  
Vol 81 (4) ◽  
pp. 241-244 ◽  
Author(s):  
Guido Ceci ◽  
Giancarlo Bisagni ◽  
Giorgio Cocconi ◽  
Carmelina Rodinò ◽  
Virginio Belsanti ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Low Dose ◽  
Objective Response ◽  
Metastatic Breast ◽  
Advanced Breast ◽  
High Dose ◽  
Severe Toxicity ◽  
Third Line ◽  
Line Chemotherapy

Aims and background The study was designed to define the activity of the combination of cisplatin and etoposide as third-line chemotherapy for advanced breast cancer and to investigate the role of the dosage of cisplatin on the effectiveness of the combination. Methods Ninety-five eligible patients with advanced breast cancer who had failed or relapsed on two previous lines of chemotherapy were randomized to receive cisplatin at a high dose (100 mg/m2 i.v. day 1, arm A) or a low dose (60 mg/m2 day 1, arm B), combined with etoposide (100 mg/m2 i.v. days 4, 6 and 8). Cycles were repeated every 3 weeks. Results Of the 78 patients evaluable for response (39 in arm A and 39 in arm B), 9 (12%) showed complete or partial response, 5 (13%) in the high-dose arm and 4 (10%) in the low-dose arm. One complete response was seen in the high-dose arm and none in the low-dose arm. The only 2 patients with brain involvement showed an objective response (one CR in arm A and one PR in arm B). Median time to progression was 14 weeks in arm A and 10 weeks in arm B, median duration of remission 28 and 34 weeks, and survival 36 and 35 weeks, respectively. The differences were not significant. As expected, the patients in the high-dose arm experienced more severe toxicity. One toxic death was observed in each arm due to sepsis in agranulocytosis. The difference was statistically significant regarding nausea and vomiting. Neurotoxicity and ototoxicity were not relevant problems in this patient setting. Conclusions Considering the very poor prognostic factors presented by these patients, the combination showed a certain activity, and further evaluation in earlier stages of disease is warranted. A particular responsiveness on brain metastases is suggested. The dose of cisplatin was not proven to be of significant importance.

scholarly journals Expanding Application of the Long-Term Quality of Life Instrument to the Population of Women Undergoing Treatment of Advanced Breast Cancer

2019 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Kendra Kamp ◽  
Megan Flanigan ◽  
Kanjana Thana ◽  
Jodi Terpstra ◽  
Gwen Wyatt ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Advanced Breast Cancer ◽  
Advanced Breast ◽  
Life Instrument

Histological Evaluation of the Effects of Intraarterial Chemotherapy for Advanced Breast Cancer: A Long-term Followup Study with Respect to the Survival Rate

Surgery Today ◽  
1998 ◽  
Vol 28 (5) ◽  
pp. 509-516 ◽  
Author(s):  
Kazunori Toda ◽  
Koichi Hirata ◽  
Takashi Sato ◽  
Minoru Okazaki ◽  
Kazuaki Asaishi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Survival Rate ◽  
Advanced Breast Cancer ◽  
Advanced Breast ◽  
Intraarterial Chemotherapy ◽  
Histological Evaluation

Long-term Survival after Cerebellar Metastasis Resection from Her2 3+ Locally Advanced Breast Cancer

2015 ◽  
Vol 11 (1) ◽  
pp. 36
Author(s):  
Zorica I Tomasevic ◽  
Zoran M Tomasevic ◽  
Zeljko Kovac ◽  
Zorka Milovanovic ◽  
Dana Grujicic ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Advanced Breast Cancer ◽  
Locally Advanced Breast Cancer ◽  
Locally Advanced ◽  
Advanced Breast ◽  
Disease Course ◽  
Term Survival ◽  
Cerebellar Metastasis ◽  
Distant Metastatic Site

We present a patient who first developed a distant metastatic site in the cerebellum during treatment for Her2 3+ locally advanced breast cancer (LABC). LABC was in complete remission at that time and isolated cerebellar metastasis was resected. The patient is still alive more than 135 months after LABC diagnosis, and more than 99 months after neurosurgery, and is still receiving trastuzumab without further progression or any toxicity. To the best of our knowledge, this is first report of such exceptional disease course for a patient with a predicted grave prognosis according to all prognostic parameters.

Sign in / Sign up

Export Citation Format

Share Document